Aurenar
Develops AI-enabled healthcare technology with backing from investors focused on women’s cardiovascular health.
Overview
Aurenar is an AI healthcare company developing technology for medical use cases. Public funding context points to a focus aligned with women’s health and cardiovascular care, given backing from the Go Red for Women Venture Fund™ and Solas BioVentures. The company has raised about $6 million across one seed round, announced as an oversubscribed $5.7 million financing. The round positions Aurenar among early-stage AI health companies attracting specialist life-sciences and cardiovascular-health investors.
Funding History
Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures
Frequently Asked Questions
- How much funding does AI Funding track for Aurenar?
- AI Funding tracks $6M for Aurenar across 1 funding round in this database.
- Who are Aurenar's investors?
- Aurenar's investors include the Go Red.
- What does Aurenar do?
- Aurenar is an AI healthcare company developing technology for medical use cases. Public funding context points to a focus aligned with women’s health and cardiovascular care, given backing from the Go Red for Women Venture Fund™ and Solas BioVentures. The company has raised about $6 million across one seed round, announced as an oversubscribed $5.7 million financing. The round positions Aurenar among early-stage AI health companies attracting specialist life-sciences and cardiovascular-health investors.
- Where is Aurenar headquartered?
- Aurenar is headquartered in San Francisco, CA.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.